Intravenous fosfomycin—back to the future. Systematic review and meta-analysis of the clinical literature

Clinical Microbiology and Infection

Volumn 23, Issue 6, 2017, Pages 363-372

  Grabein, B ^a   Graninger, W ^b   Rodriguez Bano J ^c,d   Dinh, A ^e   Liesenfeld, D B ^f  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b KARL LANDSTEINER INSTITUTE OF UROLOGY AND ANDROLOGY   (Austria)

^c HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

^e RAYMOND POINCARÉ HOSPITAL   (France)

^f InfectoPharm Arzneimittel und Consilium GmbH   (Germany)

Author keywords

Clinical outcome; Fosfomycin; Intravenous; Meta analysis; Multi drug resistance; Systematic review

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; FOSFOMYCIN; ANTIINFECTIVE AGENT;

ABDOMINAL PAIN; ANEMIA; ANTIBIOTIC RESISTANCE; ASTHENIA; BACTEREMIA; BONE AND JOINT INFECTIONS; CENTRAL NERVOUS SYSTEM INFECTION; COMBINATION DRUG THERAPY; CONJUNCTIVITIS; COUGHING; DECREASED APPETITE; DIARRHEA; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DYSGEUSIA; EDEMA; EOSINOPHILIA; ERYTHEMA MULTIFORME; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART DISEASE; HEART FAILURE; HERPES SIMPLEX; HUMAN; HYPERGLYCEMIA; HYPERHIDROSIS; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPOKALEMIA; HYPONATREMIA; INJECTION SITE PAIN; INVASIVE CANDIDIASIS; LEUKOPENIA; LUNG EDEMA; META ANALYSIS; MONOTHERAPY; MYCOSIS; NAUSEA; NEUTROPENIA; NICOLAU SYNDROME; NONKETOTIC DIABETIC COMA; PRIORITY JOURNAL; RASH; RESPIRATORY TRACT INFECTION; RETCHING; REVIEW; SEPSIS; SHOCK; SYSTEMATIC REVIEW; TACHYCARDIA; THROMBOCYTOPENIA; THROMBOPHLEBITIS; URINARY TRACT INFECTION; URTICARIA; VERTIGO; VOMITING; ADULT; BACTERIAL INFECTION; CHILD; INTRAVENOUS DRUG ADMINISTRATION; OBSERVATIONAL STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

ADMINISTRATION, INTRAVENOUS; ADULT; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CHILD; FOSFOMYCIN; HUMANS; OBSERVATIONAL STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 85011361543     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2016.12.005     Document Type: Review

References (104)

1. Kahan, F.M., Kahan, J.S., Cassidy, P.J., Kropp, H., The mechanism of action of fosfomycin (phosphonomycin). Ann N Y Acad Sci 235 (1974), 364–386.
2. Paul-Ehrlich-Gesellschaft für Chemotherapie. Resistenzstudie 2013. Abschlussbericht Teilprojekt H - Epidemiologie und Resistenzsituation bei klinisch wichtigen Infektionserregern aus dem Hospitalbereich gegenüber Antibiotika. 2015. Available at: http://www.p-e-g.org/econtext/Berichte%20der%20Studien/.
3. Allerberger, F., Klare, I., In-vitro activity of fosfomycin against vancomycin-resistant enterococci. J Antimicrob Chemother 43 (1999), 211–217.
4. Maraki, S., Samonis, G., Rafailidis, P.I., Vouloumanou, E.K., Mavromanolakis, E., Falagas, M.E., Susceptibility of urinary tract bacteria to fosfomycin. Antimicrob Agents Chemother 53 (2009), 4508–4510.
5. Falagas, M.E., Kastoris, A.C., Kapaskelis, A.M., Karageorgopoulos, D.E., Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum β-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis 10 (2010), 43–50.
6. Boyanova, L., Susceptibility of anaerobes to fusidic acid and fosfomycin. Int J Antimicrob Agents 45 (2015), 560–561.
7. Falagas, M.E., Kastoris, A.C., Karageorgopoulos, D.E., Rafailidis, P.I., Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies. Int J Antimicrob Agents 34 (2009), 111–120.
8. Pfausler, B., Spiss, H., Dittrich, P., Zeitlinger, M., Schmutzhard, E., Joukhadar, C., Concentrations of fosfomycin in the cerebrospinal fluid of neurointensive care patients with ventriculostomy-associated ventriculitis. J Antimicrob Chemother 53 (2004), 848–852.
9. Kuhnen, E., Pfeifer, G., Frenkel, C., Penetration of fosfomycin into cerebrospinal fluid across non-inflamed and inflamed meninges. Infection 15 (1987), 422–424.
10. Schintler, M.V., Traunmüller, F., Metzler, J., Kreuzwirt, G., Spendel, S., Mauric, O., et al. High fosfomycin concentrations in bone and peripheral soft tissue in diabetic patients presenting with bacterial foot infection. J Antimocrob Chemother 64 (2009), 574–578.
11. Matzi, V., Lindenmann, J., Porubsky, C., Kugler, S.A., Maier, A., Dittrich, P., et al. Extracellular concentrations of fosfomycin in lung tissue of septic patients. J Antimicrob Chemother 65 (2010), 995–998.
12. Legat, F.J., Maier, A., Dittrich, P., Zenahlik, P., Kern, T., Nuhsbaumer, S., et al. Penetration of fosfomycin into inflammatory lesions in patients wich cellulitis or diabetic foot syndrome. Antimicrob Agents Chemother 47 (2003), 371–374.
13. Parker, S.L., Frantzeskaki, F., Wallis, S.C., Diakaki, C., Giamarellou, H., Koulenti, D., et al. Population pharmacokinetics of fosfomycin in critically ill patients. Antimicrob Agents Chemother 59 (2015), 6471–6476.
14. del Río, A., Gasch, O., Moreno, A., Peña, C., Cuquet, J., Soy, D., et al. Efficacy and safety of fosfomycin plus imipenem as rescue therapy for complicated bacteremia and endocarditis due to methicillin-resistant Staphylococcus aureus: a multicenter clinical trial. Clin Infect Dis 59 (2014), 1105–1112.
15. Viechtbauer, W., Conducting meta-analyses in R with the metafor package. J Stat Software 36 (2010), 1–48.
16. Aidan, P., Francois, M., Prunel, M., Narcy, P., Cellulite de la région orbitaire chez l'enfant. Arch Pediatr 1 (1994), 879–885.
17. Badelon, O., Bingen, E., Sauzeau, C., Lambert-Zechovsky, N., de Ribier, A., Bensahel, H., [Choice of first-line antibiotic therapy in the treatment of bone and joint infections in children]. Pathol Biol (Paris) 36 (1988), 746–749.
18. Bode, U., Infektionen in der Pädiatrischen Onkologie. Adam, D., (eds.) Fosfomycin – Berichtsband zum Workshop Aktuelle Aspekte in der Infektionstherapie, 1986, Frankfurt/Main: pmi, 19–23.
19. Cedrato, A.E., Martinez Meyer, C.A., Koltan, A., Touceda, C., Del Boca, J.C., Galan, H., et al. Fosfomicina sola o asociada a otros antibioticos. Revissa Argentina de Pediatria, 3(6), 1977.
20. Chung, S.S., Iazzetti, A.V., Nobrega, F.J., Farhat, C.K., Septicemia neonatal—consideracoes etiopatogenicas terapeuticas. J pediat (Rio de J), 46(3), 1979.
21. Corti, N., Sennhauser, F.H., Stauffer, U.G., Nadal, D., Fosfomycin for the initial treatment of acute haematogenous osteomyelitis. Arch Dis Child 88 (2003), 512–516.
22. Fitoussi, F., Litzelmann, E., Ilharreborde, B., Morel, E., Mazda, K., Pennecot, G.F., Hematogenous osteomyelitis of the wrist in children. J Pediatr Orthop 27 (2007), 810–813.
23. François, M., Mariani-Kurkdjian, P., Dupont, E., Bingen, E., Acute ethmoiditis in children, a series of 125 cases. Arch pediatr 13 (2006), 6–10.
24. François, M., Mariani-Kurkdjian, P., Elbakkouri, W., Bingen, E., [Suppurative cervical lymphadenitis in children. Review of 45 patients]. Ann Otolaryngol Chir Cervicofac 121 (2004), 110–114.
25. Gouyon, J.B., Francois, C., Semama, D., Sandre, D., Duez, J.M., Portier, H., Septicemies nosocomiales a staphylocoques epidermidis et aures chez le nouveauné. Ann Pediatr Paris 37 (1990), 21–25.
26. Gouyon, J.B., Duez, J.M., Portier, H., Brichon, P., Kohli, E., Alison, M., L'association fosfomycine-céfotaxime dans les infections sévères staphylococciques du nouveau-né. La Presse Méd 14 (1985), 2135–2138.
27. Guggenbichler, J.P., Bonatti, H., Rottensteiner, F., Resistenz der Staphylokokken gegen intrazelluläre Abtötung durch Makrophagen – ein neuses pathophysiologisches Konzept der akuten hämatogenen Osteomyelitis im Kindesalter und seine therapeutischen Konsequenzen. Pädiatrie und Pädologie 24 (1989), 21–32.
28. Guggenbichler, J.P., Frisch, J., Fosfomycin in der Behandlung der eitrigen Meningitis im Früh- und Neugeborenenalter. Spitzy, K.H., Adam, D., (eds.) Fosfomycin – ein neuartiges Antibiotikum, Internationales Symposiums Salzburg 1982, 1983, Frankfurt/Zürich: pmi, 169–176.
29. Guibert, M., Magny, J.F., Poudenx, F., Lebrun, L., Dehan, M., [Comparative pharmacokinetics of fosfomycin in the neonate: 2 modes of administration]. Pathol Biol (Paris) 35 (1987), 750–752.
30. Hepping, N., Bode, U., Fleischhack, G., Wiszniewsky, G., Molitor, E., Simon, A., Fosfomycin: prospektive Analyse von 100 Behandlungskursen in einem pädiatrisch onkologischen Zentrum. Chemother J 17 (2008), 25–28.
31. Hori, M., Kono, S., Joh, K., Clinical experiences of fosfomycin (FOM) for intravenous injection against severe infantile acute bacterial infections. Chemotherapy (Jpn) 23 (1975), 3409–3414.
32. Klumpp, H., Engert, J., Körling, W., Behandlungsmöglichkeiten bei Ventilsepsis. Knothe, H., (eds.) Fosfomycin. Berichtsband zum Workshop Pädiatrie, 1985, Frankfurt/Zürich: pmi, 46–52.
33. Lagier, P., Perraud-Bimar, P., Dejode, J.M., Brun, T., Bimar, J., Expérience de la fosfomycine dans le traitement des infections sévères en réanimation pédiatrique. Ann Pédiatr (Paris) 34 (1987), 457–461.
34. Llorens, J., Ley, G., Fores, A., Olay, T., Acute infantile pneumonopathies treated with fosfomycin. Chemotherapy 23:Suppl 1 (1977), 315–323.
35. Marget, W., Lohse, K., Fosfomycin in the treatment of infections difficult to treat. Fosfomycin. Proceedings of the International Symposium. March 1986 Mexico, 1987, Instituto de Farmacología Española (CEPA), Madrid, 229–231.
36. Panico Grecco, S., de Sicca Filho, F.A., Boucas, M.E.A., Fosfomicina como terapeutica antiinfecciosa em pediatria. A Folha Medica, 77(3), 1978.
37. Pillwein, K., Guggenbichler, P., Konzert, W., Fosfomycin in der Behandlung der akuten hämatogenen Osteomyelitis im Säuglingsalter. Spitzy, K.H., Adam, D., (eds.) Fosfomycin - ein neuartiges Antibiotikum, Internationales Symposiums Salzburg 1982, 1983, Frankfurt/Zürich: pmi, 181–195.
38. Reinehr, T., Bürk, G., Michel, E., Andler, W., Chronic osteomyelitis in childhood: is surgery always indicated?. Infection 28 (2000), 282–286.
39. Riedl, M., Allerberger, F., Guggenbichler, J.P., Semenitz, E., Dierich, M.P., Behandlung von Sepsiserkrankungen im Kindesalter mit zeitlich versetzter Gabe von Antibiotika-Kombinationen. Wien Medizin Wochenschr 141 (1991), 172–176.
40. Roche, G., Bollaert, P.E., Gerard, A., Canton, Ph, Weber, M., Czorny, A., et al. Infections a cocci Gram positif au cours des dérivations de L.C.R. Traitment par l'association Fosfomycine-Oxacilline. Med Maladies Infect 13 (1983), 426–427.
41. Rossignol, S., Regnier, C., La fosfomycine dans les infections sévères en nèonatologie. Ann Pédiat (Paris) 31 (1984), 437–444.
42. Sawada, S., [Clinical experience with fosfomycin for intravenous use in respiratory infections]. Chemotherapy (Jpn) 23 (1975), 3406–3408.
43. Baquero, F., Hortelano, J.G., Navarro, M., Scarpellini, A., Jara, P., Cañedo, T., et al. Antibiotherapy of Serratia marcescens septicemia in children. Chemotherapy 23:Suppl 1 (1977), 416–422.
44. Dinh, A., Salomon, J., Bru, J.P., Bernard, L., Fosfomycin: efficacy against infections caused by multidrug-resistant bacteria. Scand J Infect Dis 44 (2012), 182–189.
45. Boulard, G., Quentin, C., Scontrini, G., Dautheribes, M., Pouguet, P., Sabathie, M., Traitement des ventriculites a Staphylococcus epidermidis sur materiel par l'association fosfomycine-aminoside. Evolution des taux ventriculaires de fosfomycine. Pathol Biol Paris 31 (1983), 525–527.
46. Dureux, J.B., Voiriot, P., Gerard, A., Maillard, S., Tronel, H., Canton, P., Expérience de la fosfomycine dans le traitement des septicémies à staphylocoque. Sem Hop Paris 63 (1987), 3556–3558.
47. Fleurette, J., Estanove, S., Brun, Y., Meyer, P., Reverdy, M.E., Ros, A., et al. Interet de la fosfomycine en association dans le traitement des infections graves. Lyon Med 244 (1980), 191–195.
48. Gobernado, M., Santos, M., Paz, M., Roman, J., Masceros, E., Five years’ experience with fosfomycin in a Spanish hospital. Bacteriological and clinical results. Siegenthaler, W., Lüthy, R., (eds.) Current Chemotherapy. Proceedings of the 10th International Congress on Chemotherapy, 1978, Zurich/Swizerland, 677–679.
49. Hernandesz-Casado, V., Fosfomycin in a traumatological department. Chemotherapy 23:Suppl 1 (1977), 403–410.
50. Itami, Y., Kobayakawa, H., Ohto, T., Yoshida, M., Ueno, H., Nishikawa, M., et al. [Basic and clinical studies on fosfomycin in orthopedic field]. Chemotherapy (Jpn) 23 (1975), 3686–3693.
51. May, T., Weber, M., Gérard, A., Schmit, J.L., Voiriot, P., Czorny, A., et al. [Treatment of post-traumatic and post-neurosurgical bacterial meningitis with ceftriaxone alone or in combination with fosfomycin]. Pathol Biol (Paris) 35 (1987), 839–842.
52. Pardo Zubiris, A., Gimeno Blasco, L., Andonegui Oteiza, J., Evaluation of Fosfomycin in an Intensive Care Unit. Chemotherapy 23:Suppl 1 (1977), 411–415.
53. Perea, E.J., Damaso, D., Moreno-Lopes, M., Rodriguez, A., Infecciones diversas tratadas con fosfomicina. Progr terapéut clín 27 (1974), 1–15.
54. Portier, H., Tremeaux, J.C., Chavanet, P., Gouyon, J.B., Duez, J.M., Kazmierczak, A., Treatment of severe staphylococcal infections with cefotaxime and fosfomycin in combination. J Antimicrob Chemother 14:Suppl B (1984), 277–284.
55. Ruiz Moyano, J., Sicilia, T., Fosfomicina en meningitis neumococica. Inmunologika 2:Suppl. 1 (1981), 84–86.
56. Sicilia, T., Estevez, E., Rodriguez, A., Fosfomycin penetration into the cerebrospinal fluid of patients with bacterial meningitis. Chemotherapy 27 (1981), 405–413.
57. Stammberger, H., [Fosfomycin – a new antibiotic in rhinootolaryngology]. HNO 31 (1983), 436–439.
58. Yano, T., Hara, H., Goto, T., Therapeutic experience of intravenous fosfomycin (Fom-Na) in orthopedical field. Chemotherapy (Jpn) 23 (1975), 3525–3527.
59. Misawa, S., Tsuda, S., Taniwaki, M., Horiike, S., Ariyama, Y., Hirakawa, K., et al. [A combined consecutive therapy with fosfomycin and sulbactam/cefoperazone for bacterial infections associated with hematological diseases]. Jpn J Antibiot 48 (1995), 514–521.
60. Tsuda, S., Kuzuyama, Y., Nakai, H., Seriu, T., Takashima, T., Tanaka, S., et al. [Clinical evaluation of imipenem/cilastatin sodium and fosfomycin as second-line combination chemotherapy in severe infections associated with hematologic disorders]. Jpn J Antibiot 46 (1993), 171–183.
61. Hiraoka, A., Hasegawa, H., Horiuchi, A., Masaoka, T., [Combination effect of fosfomycin and sulbactam/cefoperazone for opportunistic infections in patients with hematological disorders: a randomised crossover trial of sequential administration]. Blood, 88(Suppl. Pt 1), 1996.
62. Kitamura, K., Hirai, H., Hosoya, N., Sugai, M., Karasawa, M., Naruse, T., et al. [Clinical efficacy of fosfomycin in combination with sulbactam/cefoperazone in the treatment of severe infections complicated to blood dyscrasia. Working Group of Kanto Combination Therapy for FOM + SBT/CPZ]. Kansenshogaku Zasshi 72 (1998), 761–770.
63. Hirakawa, K., Tsuda, S., Misawa, S., Ueda, Y., Kaneko, H., Nakao, M., et al. [Clinical effects of a combination treatment with fosfomycin and clavulanic acid/ticarcillin for infections in patients complicated with hematological disorders]. Jpn J Antibiot 47 (1994), 521–529.
64. Sano, S., Karino, K., Nakano, K., Watanabe, T., Masahiro, H., [Comparative study of the efficacy on fosfomycin Na and sulbenicilin Na against the chronic urinary tract infections by Pseudomonas aeruginosa and Proteus vulgaris]. Acta Urol Jpn, 25(1), 1979.
65. Kobashi, Y., Ohba, H., Okimoto, N., Tada, A., Kawahara, S., Ishida, T., et al. Clinical analysis of combined consecutive therapy with fosfomycin and sulbactam/cefoperazone for patients with pneumonia. Jpn J Chemother 50 (2002), 429–434.
66. Shimokata, K., Torigai, K., Kato, M., Sakai, S., Nomura, F., Ito, T., et al. [Effects of cefotaxime single administration and of cefotaxime + fosfomycin administration against respiratory tract infections]. Jpn J Antibiot 41 (1988), 1261–1271.
67. Sirijatuphat, R., Thamlikitkul, V., Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections. Antimicrob Agents Chemother 58 (2014), 5598–5601.
68. Ode, B., Haidl, S., Hoffstedt, B., Walder, M., Ursing, J., Fosfomycin versus ampicillin in the treatment of acute pyelonephritis. Chemioterapia 7 (1988), 96–100.
69. Nissen, L.R., Jacobsen, J., Ravn, T.J., Wahlgreen, C., Auning-Hansen, H., Fosfomycin-ampicillin versus gentamicin-ampicillin in the treatment of critically ill patients with pneumonia. Infection 14 (1986), 246–249.
70. Zhang, J.J., [Observations on the effect of sodium fosfomycin on the lower respiratory tract infection]. Chin J Antibiotics 28 (2003), 361–363.
71. Otsuka, M., Sawahata, T., Nakai, T., Hasegawa, S., Iwata, S., Yoshizawa, Y., et al. [Efficacy of combination therapy against MRSA in Ibaraki Prefecture]. Jpn J Antibiot 47 (1994), 781–789.
72. Albano, V., Giambanco, V., Alio, L., Note cliniche sull'impiego della fosfomicina in ostetricia e ginecologia. Boil Chim Farm 117 (1978), 428–431.
73. Baron, D., Touze, M.D., Tasseau, F., Reynaud, A., Derriennic, M., Courtieu, A.L., Comparaison entre fosfomycine-pénicilline M et pénicilline M-Gentamicine. A propos de 35 infections sévères à Staphylococcus aureus méticilline-sensibles. Rev Méd interne 8 (1987), 109–114.
74. Apisarnthanarak, A., Mundy, L.M., Carbapenem-resistant Pseudomonas aeruginosa pneumonia with intermediate minimum inhibitory concentrations to doripenem: combination therapy with high-dose, 4-h infusion of doripenem plus fosfomycin versus intravenous colistin plus fosfomycin. Int J Antimicrob Agents 39 (2012), 271–272.
75. Matsumoto, T., Kubo, S., Haraoka, M., Takahashi, K., Tanaka, M., Sakumoto, M., et al. Combination chemotherapy for infections due to methicillin-resistant Staphylococcus aureus with combination therapy by cefuzonam and fosfomycin or minocycline in the urologic field. Clin Ther 15 (1993), 819–828.
76. Guerrero, A., Diaz-Peletier, R., Hellin, T., Fosfomycin in the treatment of osteomyelitis. Fosfomycin. Proceedings of the International Symposium. March 1986 Mexico, 1987, Instituto de Farmacología Española (CEPA), Madrid, 136–144.
77. Baron, D., Desjars, P., Touze, M.D., Tasseau, F., Potel, G., Clinical Study on combined therapy with fosfomycin for staphylococcal infections. Fosfomycin. Proceedings of the International Symposium. March 1986 Mexico, 1987, Instituto de Farmacología Española (CEPA), Madrid, 172–187.
78. Baron, D., Drugeon, H., Septicemias e infecciones óseas por Staphylococcus aureus resistentes a la meticilina y a los aminoglucósidos. Tratamiento con fosfomicina-oxacilina. Inmunologika. Edición especial: 3rd international symposium on Fosfomycin on the occasion of the 25th Anniversary of 1st Research Center Instituto de Farmacología Espanola, 1981, 80–83.
79. Baron, D., Drugeon, H.B., Touze, M.D., Derrienic, M., Tasseau, F., Reynaud, A., Les infections a staphylocoques meticilline-resistants. Pocidalo, J.J., Vachon, F., (eds.) Problèmes actuels de pathologie infectieuse et de réanimation, 1984, Arnette, Paris, 1–24.
80. Kono, K., Takeda, S., Tatara, I., Arakawa, K., Tanaka, H., Miyake, S., et al. Combined therapy with arbekacin and fosfomycin for methicillin-resistant Staphylococcus aureus infections. Jpn J Antibiotics 47 (1994), 798–803.
81. Lau, W.Y., Teoh-Chan, C.H., Fan, S.T., Lau, K.F., In vitro and in vivo study of fosfomycin in methicillin-resistant Staphylococcus aureus septicaemia. J Hyg Camb 96 (1986), 419–432.
82. May, T., Janbon, F., Beuscart, C., Meyran, M., Roue, R., [Severe infections caused by methicillin-resistant Staphylococcus aureus. 62 cases]. Presse Med 22 (1993), 909–913.
83. Apisarnthanarak, A., Mundy, L.M., Use of high-dose 4-hour infusion of doripenem, in combination with fosfomycin, for treatment of carbapenem-resistant Pseudomonas aeruginosa pneumonia. Clin Infect Dis 51 (2010), 1351–1352.
84. Michalopoulos, A., Virtzili, S., Rafailidis, P., Chalevelakis, G., Damala, M., Falagas, M.E., Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation. Clin Microbiol Infect 16 (2010), 184–186.
85. Pontikis, K., Karaiskos, I., Bastani, S., Dimopoulos, G., Kalogirou, M., Katsiari, M., et al. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria. International J Antimicrob Agents 43 (2014), 52–59.
86. Stöckl, B., Schmutzhard, E., Antimikrobielle Therapie der Spondylodiszitis – Überlegungen zur Optimierung. Chemother J 14 (2005), 11–15.
87. Stengel, D., Görzer, E., Schintler, M., Legat, F.J., Amann, W., Pieber, T., et al. Second-line treatment of limb-threatening diabetic foot infections with intravenous fosfomycin. J Chemother 17 (2005), 527–535.
88. Timmler, R., Sauer, W., Klinische Prüfung BM 04.005 (Fosfomycin). Abschlussbericht für die 4-Gramm-Tagesdosis. Klinische Entwicklung Abteilung Chemotherapie. 1978, Boehringer Mannheim GmbH.
89. Timmler, R., Sauer, W., Klinische Prüfung BM 04.005 (Fosfomycin). Abschlussbericht für die 6-Gramm-Tagesdosis. Klinische Entwicklung Abteilung Chemotherapie. 1978, Boehringer Mannheim GmbH.
90. Quentin, C., Boulard, G., Bebear, C., Sabathie, M., Ventricular fluid concentration of fosfomycin in patients with ventriculitis. Brumfitt, W., Finland, M., (eds.) Proceedings of the 13th International Congress of Chemotherapy, 1983, H. Egermann, Viena, 8–12 SS 4.6/8 part 37.
91. Meissner, A., Haag, R., Rahmanzadeh, R., Adjuvant fosfomycin medication in chronic osteomyelitis. Infection 17 (1989), 146–151.
92. Naber, K.G., Timmler, R., Keimelimination durch Fosfomycin bei komplizierten Harnwegsinfektionen. Therapiewoche 33 (1983), 3300–3306.
93. Gudin, J., Santos, M., Ruano, M., Rafecas, J., Gobernado, M., Fosfomycin in the treatment of septicemia. Fosfomycin. Proceedings of the International Symposium. March 1986 Mexico, 1987, Instituto de Farmacología Española (CEPA), Madrid, 166–171.
94. Bertoye, A., Vincent, P., Fournier, G., Marcel, J.P., Olivier, G., Fournier, G., Traitement par la fosfomycine des infections severes observees en service de reanimation. Lyon Med 243 (1980), 177–182.
95. Federspil, P., Schätzle, W., Schedler, M., Wirksamkeit, Nebenwirkungen und Pharmakokinetik von Fosfomycin bei Hals-Nasen-Ohren-Infektionen. Therapiewoche 33 (1983), 4372–4382.
96. Peters, H.J., Eicher, R., Klinische Erfahrungen mit Fosfomycin bei Harnwegsinfektionen. MMW Munch Med Wochenschr 123 (1981), 748–750.
97. Peters, H.J., Eicher, R., Fosfomycin, klinische Wirksamkeit und Verträglichkeit bei Harnwegsinfektionen. Klinikarzt 11 (1982), 168–180.
98. Santimaleeworagun, W., Wongpoowarak, P., Chayakul, P., Pattharachayakul, S., Tansakul, P., Garey, K.W., In vitro activity of colistin or sulbactam in combination with fosfomycin or imipenem against clinical isolates of carbapenem-resistant Acinetobacter baumannii producing OXA-23 carbapenemases. Southeast Asian J Trop Med Public Health 42 (2011), 890–900.
99. The European Committee on Antimicrobial Susceptibility Testing, Breakpoint tables for interpretation of MICs and zone diameters. Version 6.0, 2016 Available at: http://www.eucast.org.
100. Milatovic, D., Braveny, I., Development of resistance during antibiotic therapy. Eur J Clin Microbiol 6 (1987), 234–244.
101. Fish, D.N., Piscitelli, S.C., Danzinger, L.H., Development of resistance during antimicrobial therapy: a review of antibiotic classes and patient characteristics in 173 studies. Pharmacotherapy 15 (1995), 279–291.
102. Karageorgopoulos, D.E., Wang, R., Yu, X.H., Falagas, M.E., Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens. J Antimicrob Chemother 67 (2012), 255–268.
103. Rosso-Fernández, C., Sojo-Dorado, J., Barriga, A., Lavín-Alconero, L., Palacios, Z., López-Hernández, I., et al. Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial. BMJ Open, 5, 2015, e007363.
104. Shaw, E., Miró, J.M., Puig-Asensio, M., Pigrau, C., Barcenilla, F., Murillas, J., et al. Daptomycin plus fosfomycin versus daptomycin monotherapy in treating MRSA: protocol of a multicentre, randomised, phase III trial. BMJ Open, 5(3), 2015, e006723.